TELBIVUDINE: 434 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
434
Total FAERS Reports
27 (6.2%)
Deaths Reported
106
Hospitalizations
434
As Primary/Secondary Suspect
5
Life-Threatening
14
Disabilities
Apr 28, 2009
FDA Approved
Discontinued
Status
FDA Application: 022011 ·
First Report: 2004 · Latest Report: 20200629
What Are the Most Common TELBIVUDINE Side Effects?
#1 Most Reported
Drug resistance
103 reports (23.7%)
#2 Most Reported
Blood creatine phosphokinase increased
84 reports (19.4%)
#3 Most Reported
Foetal exposure during pregnancy
58 reports (13.4%)
All TELBIVUDINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug resistance | 103 | 23.7% | 0 | 10 |
| Blood creatine phosphokinase increased | 84 | 19.4% | 2 | 43 |
| Foetal exposure during pregnancy | 58 | 13.4% | 13 | 3 |
| Myalgia | 49 | 11.3% | 2 | 22 |
| Drug ineffective | 37 | 8.5% | 0 | 6 |
| Pathogen resistance | 37 | 8.5% | 0 | 6 |
| Muscular weakness | 33 | 7.6% | 1 | 19 |
| Maternal exposure during pregnancy | 31 | 7.1% | 0 | 3 |
| Treatment failure | 31 | 7.1% | 0 | 0 |
| Asthenia | 26 | 6.0% | 3 | 18 |
| Viral mutation identified | 25 | 5.8% | 0 | 0 |
| Rhabdomyolysis | 24 | 5.5% | 3 | 12 |
| Hepatic cirrhosis | 20 | 4.6% | 5 | 16 |
| Myopathy | 20 | 4.6% | 0 | 12 |
| Vomiting | 20 | 4.6% | 5 | 14 |
| Hypoaesthesia | 19 | 4.4% | 0 | 11 |
| Gait disturbance | 18 | 4.2% | 0 | 10 |
| Pain in extremity | 18 | 4.2% | 1 | 11 |
| Alanine aminotransferase increased | 17 | 3.9% | 1 | 8 |
| Fatigue | 17 | 3.9% | 1 | 11 |
Who Reports TELBIVUDINE Side Effects? Age & Gender Data
Gender: 37.4% female, 62.6% male. Average age: 43.4 years. Most reports from: CN. View detailed demographics →
Is TELBIVUDINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2004 | 11 | 6 | 1 |
| 2007 | 8 | 0 | 2 |
| 2008 | 6 | 1 | 5 |
| 2010 | 4 | 0 | 1 |
| 2011 | 5 | 0 | 2 |
| 2012 | 21 | 1 | 11 |
| 2013 | 25 | 0 | 10 |
| 2014 | 35 | 0 | 8 |
| 2015 | 16 | 0 | 11 |
| 2016 | 25 | 0 | 13 |
| 2017 | 12 | 0 | 8 |
| 2018 | 13 | 2 | 3 |
| 2019 | 9 | 2 | 1 |
| 2020 | 2 | 0 | 1 |
What Is TELBIVUDINE Used For?
| Indication | Reports |
|---|---|
| Chronic hepatitis b | 153 |
| Hepatitis b | 111 |
| Product used for unknown indication | 52 |
| Foetal exposure during pregnancy | 30 |
| Hiv infection | 20 |
| Hepatic cirrhosis | 12 |
| Antiviral treatment | 11 |
| Viral infection | 9 |
| Hepatitis viral | 8 |
TELBIVUDINE vs Alternatives: Which Is Safer?
TELBIVUDINE vs TELMISARTAN
TELBIVUDINE vs TELOTRISTAT ETHYL
TELBIVUDINE vs TEMAZEPAM
TELBIVUDINE vs TEMODAR
TELBIVUDINE vs TEMOZOLOMIDE
TELBIVUDINE vs TEMSIROLIMUS
TELBIVUDINE vs TENAMFETAMINE
TELBIVUDINE vs TENAPANOR
TELBIVUDINE vs TENECTEPLASE
TELBIVUDINE vs TENELIGLIPTIN
Official FDA Label for TELBIVUDINE
Official prescribing information from the FDA-approved drug label.